Instant and supersaturated dissolution of naproxen and sesamin (poorly water-soluble drugs and supplements) nanoparticles prepared by continuous expansion of liquid carbon dioxide solution through long dielectric nozzle
Source abstract
Abstract
Nanoparticles (NPs) of naproxen (a nonsteroidal anti-inflammatory drug, BCS Class 2) and sesamin (a poorly water-soluble lignan) were investigated. By applying a newly developed rapid expansion system of liquid carbon dioxide solutions equipped with a dielectric nozzle, well-separated and fine both naproxen NPs (averaged particle size (APS) = 46.9 nm) and sesamin NPs (APS = 60.2 nm) were obtained without heating, surfactants, and co-solvents. Obtained naproxen and sesamin NPs had large surface/weight ratio, therefore, they showed instant dissolution to water until about ten percent higher than the saturated concentrations. In addition, the technique developed in the study has big advantage on producing especially drug NPs because the NPs produced by the method never includes neither poisonous additives (especially co-solvents and detergents) nor thermally denatured compounds.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Microencapsulation and Drying Processes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Amidon GL, Lennernäs H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413–42010.1023/A:1016212804288 ↗
2. Bertram SH, Van der Steur JPK, Aterman HI (1928) Biochem Z 197:1
3. Cansell F, Aymonier C, Loppinet-Serani A (2003) Review on materials science and supercritical fluids. Curr Opin Solid State Mater Sci 7(4–5):331–34010.1016/j.cossms.2004.01.003 ↗
4. Cerdeira AM, Mazzotti M, Gander B (2010) Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int J Pharm 396(1–2):210–21810.1016/j.ijpharm.2010.06.020 ↗
5. Chiou WL, Riegelman S (1971) Pharmaceutical applications of solid dispersion systems. J Pharm Sci 60(9):1281–130210.1002/jps.2600600902 ↗
6. Craig DQM (2002) The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 231(2):131–14410.1016/S0378-5173(01)00891-2 ↗
7. Hwang J, Rodgers K, Oliver JC, Schleup T (2008) α-Methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int J Nanomed 3(3):359–371
8. Imran ul-haq M, Chasovskikh E, Signorell R (2010) Phase behavior of ketoprofen-poly(lactic acid) drug particles formed by rapid expansion of supercritical solutions. Langmuir 26(18):14951–1495710.1021/la1026224 ↗
9. Jinno J-i, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T (2006) Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 111(1–2):56–6410.1016/j.jconrel.2005.11.013 ↗
10. Jung J, Perrut M (2001) Particle design using supercritical fluids: literature and patent survey. J Supercrit Fluids 20(3):179–21910.1016/S0896-8446(01)00064-X ↗
11. Junghanns J-UAH, Mueller RH (2008) Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 3(3):295–309
12. Keck CM, Müller RH (2006) Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62(1):3–1610.1016/j.ejpb.2005.05.009 ↗
13. Kenyon CJ, Hooper G, Tierney D, Butler J, Devane J, Wilding IR (1995) The effect of food on the gastrointestinal transit and systemic absorption of naproxen from a novel sustained release formulation. J Control Release 34(1):31–3610.1016/0168-3659(94)00118-E ↗
14. Laine L, Sloane R, Ferretti M, Cominelli F (1995) A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 42(5):428–43310.1016/S0016-5107(95)70045-5 ↗
15. Liversidge GG, Conzentino P (1995) Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 125(2):309–31310.1016/0378-5173(95)00148-C ↗
16. Liversidge GG, Cundy KC (1995) Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 125(1):91–9710.1016/0378-5173(95)00122-Y ↗
17. Löbenberg R, Amidon GL (2000) Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50(1):3–1210.1016/S0939-6411(00)00091-6 ↗
18. Merisko-Liversidge E, Liversidge GG, Cooper ER (2003) Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18(2):113–12010.1016/S0928-0987(02)00251-8 ↗
19. Moribe K, Shibata M, Furuishi T, Higashi K, Tomono K, Yamamoto K (2010) Effect of particle size on skin permeation and retention of piroxicam in aqueous suspension. Chem Pharm Bull 58(8):1096–109910.1248/cpb.58.1096 ↗
20. Peinemann K (1896) Arch Pharm 234:238
21. Peñalvo J, Hopia A, Adlercreutz H (2006) Effect of sesamin on serum cholesterol and triglycerides levels in LDL receptor-deficient mice. Eur J Nutr 45(8):439–44410.1007/s00394-006-0617-8 ↗
22. Phillips EM, Stella VJ (1993) Rapid expansion from supercritical solutions: application to pharmaceutical processes. Int J Pharm 94(1–3):1–1010.1016/0378-5173(93)90002-W ↗
23. Poling BE, Prausnitz JM, O’Coneell JP (2001) The properties of gases and liquids, 5th edn. McGraw-Hill, New York
24. Rao CBS (ed) (1978) Chemistry of lignans. Andhra University Press, Visakhapatnam
25. Shao N, Su Y, Hu J, Zhang J, Zhang H, Cheng Y (2011) Comparison of generation 3 polyamidoamine dendrimer and generation 4 polypropylenimine dendrimer on drug loading, complex structure, release behavior, and cytotoxicity. Int J Nanomed 6:3361–3372
26. Span R, Wagner W (1996) A new equation of state for carbon dioxide covering the fluid region from the triple-point temperature to 1100 K at pressures up to 800 MPa. J Phys Chem Ref Data 25(6):150910.1063/1.555991 ↗
27. Subramaniam B, Rajewski RA, Snavely K (1997) Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci 86(8):885–89010.1021/js9700661 ↗
28. Tanaka N, Imai K, Okimoto K, Ueda S, Tokunaga Y, Ohike A, Ibuki R, Higaki K, Kimura T (2005) Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine. J Control Release 108(2–3):386–39510.1016/j.jconrel.2005.08.024 ↗
29. Tanaka N, Imai K, Okimoto K, Ueda S, Tokunaga Y, Ibuki R, Higaki K, Kimura T (2006) Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation. J Control Release 112(1):51–5610.1016/j.jconrel.2006.01.020 ↗
30. Tanaka Y, Inkyo M, Yumoto R, Nagai J, Takano M, Nagata S (2009) Nanoparticulation of poorly water soluble drugs using a wet-mill process and physicochemical properties of the nanopowders. Chem Pharm Bull 57(10):1050–105710.1248/cpb.57.1050 ↗
31. Tozuka Y, Miyazaki Y, Takeuchi H (2010) A combinational supercritical CO2 system for nanoparticle preparation of indomethacin. Int J Pharm 386(1–2):243–24810.1016/j.ijpharm.2009.10.044 ↗
32. Uchida H, Manaka A, Matsuoka M, Takiyama H (2004) Growth phenomena of single crystals of naphthalene in supercritical carbon dioxide. Cryst Growth Des 4(5):937–94210.1021/cg034212u ↗
33. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, Higaki K, Kimura T (2003) Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 267(1–2):79–9110.1016/j.ijpharm.2003.07.010 ↗
34. Yeo SD, Kiran E (2005) Formation of polymer particles with supercritical fluids: a review. J Supercrit Fluids 34(3):287–30810.1016/j.supflu.2004.10.006 ↗
35. York P (1999) Strategies for particle design using supercritical fluid technologies. Pharm Sci Technol Today 2(11):430–44010.1016/S1461-5347(99)00209-6 ↗